JP2005501802A - 虚血心筋を処置するための限局性心筋注入方法 - Google Patents
虚血心筋を処置するための限局性心筋注入方法 Download PDFInfo
- Publication number
- JP2005501802A JP2005501802A JP2002563950A JP2002563950A JP2005501802A JP 2005501802 A JP2005501802 A JP 2005501802A JP 2002563950 A JP2002563950 A JP 2002563950A JP 2002563950 A JP2002563950 A JP 2002563950A JP 2005501802 A JP2005501802 A JP 2005501802A
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- therapeutic agent
- ischemic
- tissue
- fgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 95
- 210000004165 myocardium Anatomy 0.000 title claims abstract description 45
- 230000002107 myocardial effect Effects 0.000 title claims description 20
- 238000002347 injection Methods 0.000 title description 27
- 239000007924 injection Substances 0.000 title description 27
- 239000003814 drug Substances 0.000 claims abstract description 64
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 230000033115 angiogenesis Effects 0.000 claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 17
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 16
- 230000001575 pathological effect Effects 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 239000013598 vector Substances 0.000 claims description 46
- 210000001519 tissue Anatomy 0.000 claims description 43
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 35
- 230000017531 blood circulation Effects 0.000 claims description 27
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 239000013603 viral vector Substances 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 241000701161 unidentified adenovirus Species 0.000 claims description 16
- 108091026890 Coding region Proteins 0.000 claims description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 13
- 230000008828 contractile function Effects 0.000 claims description 10
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 8
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 8
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 8
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 8
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims description 8
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims description 8
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 7
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 claims description 7
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 claims description 7
- 102000009840 Angiopoietins Human genes 0.000 claims description 6
- 108010009906 Angiopoietins Proteins 0.000 claims description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 claims description 6
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 6
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 claims description 6
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 6
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 6
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 6
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 241000252233 Cyprinus carpio Species 0.000 claims description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 208000000059 Dyspnea Diseases 0.000 claims description 2
- 206010013975 Dyspnoeas Diseases 0.000 claims description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 102100020880 Kit ligand Human genes 0.000 claims description 2
- 108010039445 Stem Cell Factor Proteins 0.000 claims description 2
- 230000005465 channeling Effects 0.000 claims description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 208000013220 shortness of breath Diseases 0.000 claims description 2
- 230000008477 smooth muscle tissue growth Effects 0.000 claims description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims 5
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 claims 5
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 5
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 5
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 4
- 102000058223 human VEGFA Human genes 0.000 claims 4
- 101150050438 NPPA gene Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 101150021185 FGF gene Proteins 0.000 claims 1
- 101100519221 Homo sapiens PDGFB gene Proteins 0.000 claims 1
- 101000602164 Homo sapiens Platelet-derived growth factor subunit A Proteins 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000001625 cardiomyogenic effect Effects 0.000 claims 1
- 230000001114 myogenic effect Effects 0.000 claims 1
- 230000004217 heart function Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 description 33
- 238000001415 gene therapy Methods 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 15
- 108700019146 Transgenes Proteins 0.000 description 12
- 238000001802 infusion Methods 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 102000008076 Angiogenic Proteins Human genes 0.000 description 9
- 108010074415 Angiogenic Proteins Proteins 0.000 description 9
- 241000282887 Suidae Species 0.000 description 9
- 230000002491 angiogenic effect Effects 0.000 description 8
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 229960001089 dobutamine Drugs 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002592 echocardiography Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 230000015624 blood vessel development Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000002586 coronary angiography Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000629029 Homo sapiens Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 description 1
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102100034296 Natriuretic peptides A Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101100244894 Sus scrofa PR39 gene Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- -1 hkis Proteins 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26346801P | 2001-01-23 | 2001-01-23 | |
| PCT/US2002/003118 WO2002064157A2 (en) | 2001-01-23 | 2002-01-23 | Localized myocardial injection method for treating ischemic myocardium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005501802A true JP2005501802A (ja) | 2005-01-20 |
| JP2005501802A5 JP2005501802A5 (https=) | 2005-12-22 |
Family
ID=23001908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563950A Pending JP2005501802A (ja) | 2001-01-23 | 2002-01-23 | 虚血心筋を処置するための限局性心筋注入方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20020172663A1 (https=) |
| EP (1) | EP1361896A2 (https=) |
| JP (1) | JP2005501802A (https=) |
| CA (1) | CA2433936A1 (https=) |
| WO (1) | WO2002064157A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011503207A (ja) * | 2007-11-16 | 2011-01-27 | サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288521B2 (en) | 2000-04-06 | 2007-10-30 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
| US7166280B2 (en) | 2000-04-06 | 2007-01-23 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
| US20100303769A1 (en) * | 2000-04-06 | 2010-12-02 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
| US7291597B2 (en) * | 2000-04-06 | 2007-11-06 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
| US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
| US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| JP4653952B2 (ja) | 2001-12-07 | 2011-03-16 | サイトリ セラピューティクス インコーポレイテッド | 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法 |
| US20050048035A1 (en) | 2001-12-07 | 2005-03-03 | Fraser John K. | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders |
| US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
| KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
| US20040258669A1 (en) * | 2002-11-05 | 2004-12-23 | Dzau Victor J. | Mesenchymal stem cells and methods of use thereof |
| US7627373B2 (en) | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| CA2516510C (en) * | 2003-02-20 | 2012-07-10 | Macropore Biosurgery, Inc. | Method of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
| US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
| US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
| EP1827494A4 (en) * | 2004-11-18 | 2010-02-17 | Wayne Franco | COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES |
| US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
| US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
| US20100028312A1 (en) * | 2005-03-24 | 2010-02-04 | Caritas St. Elizabeth Medical Center of Boston Inc | Stably transformed bone marrow-derived cells and uses thereof |
| US7774057B2 (en) | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
| US20110076255A1 (en) | 2005-11-07 | 2011-03-31 | Pecora Andrew L | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
| US8637005B2 (en) | 2005-11-07 | 2014-01-28 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
| MY147516A (en) * | 2005-11-07 | 2012-12-31 | Amorcyte Inc | Compositions and method of vascular injury repair cross-reference to related applications |
| US20070190028A1 (en) * | 2006-02-13 | 2007-08-16 | Jihong Qu | Method and apparatus for heat or electromagnetic control of gene expression |
| US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
| WO2010021993A1 (en) | 2008-08-19 | 2010-02-25 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
| CN102245189B (zh) | 2008-12-03 | 2015-06-17 | 阿莫塞特公司 | 改善梗死区灌注的组合物以及血管损伤修复方法 |
| KR101738324B1 (ko) | 2009-05-01 | 2017-05-19 | 비미니 테크놀로지스 엘엘씨 | 조직 및 세포 부유화 이식편의 최적화 시스템, 방법 및 조성물 |
| WO2010138180A2 (en) * | 2009-05-26 | 2010-12-02 | The University Of Vermont And State Agriculture College | Compositions and methods for cardiac tissue repair |
| WO2013138338A2 (en) | 2012-03-12 | 2013-09-19 | Massachusetts Institute Of Technology | Methods for treating tissue damage associated with ischemia with apoliporotein d |
| CN105682676B (zh) | 2013-10-22 | 2020-10-23 | 赫利世弥斯株式会社 | 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物 |
| RU2570285C1 (ru) * | 2014-11-25 | 2015-12-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения субкритической ишемии конечности на фоне хронических облитерирующих заболеваний артерий нижних конечностей |
| CA2973096A1 (en) | 2015-01-06 | 2016-07-14 | Cardiovascular Biotherapeutics, Inc. | Angiogenic treatment of ischemic heart disease |
| AU2016220304B2 (en) | 2015-02-16 | 2019-07-25 | Venturis Therapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
| US10813612B2 (en) | 2019-01-25 | 2020-10-27 | Cleerly, Inc. | Systems and method of characterizing high risk plaques |
| US11501436B2 (en) | 2020-01-07 | 2022-11-15 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| US20220392065A1 (en) | 2020-01-07 | 2022-12-08 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| US11969280B2 (en) | 2020-01-07 | 2024-04-30 | Cleerly, Inc. | Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking |
| KR20220090951A (ko) * | 2020-12-23 | 2022-06-30 | 건국대학교 산학협력단 | 섬유아세포 성장인자의 신규 단편 및 이의 용도 |
| CN114053224A (zh) * | 2021-09-07 | 2022-02-18 | 山东第一医科大学附属省立医院(山东省立医院) | 含βARKct的脂质体复合物及其制备方法和应用 |
| US20250217981A1 (en) | 2022-03-10 | 2025-07-03 | Cleerly, Inc. | Systems, methods, and devices for image-based plaque analysis and risk determination |
| US12406365B2 (en) | 2022-03-10 | 2025-09-02 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| US20250143657A1 (en) | 2022-03-10 | 2025-05-08 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
| US12440180B2 (en) | 2022-03-10 | 2025-10-14 | Cleerly, Inc. | Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661133B1 (en) * | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
| US5221272A (en) * | 1991-12-03 | 1993-06-22 | Safegrip, Inc. | Unified medical fluid system |
| JPH08506008A (ja) * | 1992-11-18 | 1996-07-02 | アーチ ディベロプメント コーポレイション | 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入 |
| US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| GB9401447D0 (en) * | 1994-01-26 | 1994-03-23 | Ciba Geigy Ag | Pharmaceutical compositions |
| US7186688B1 (en) * | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
| US6152141A (en) * | 1994-07-28 | 2000-11-28 | Heartport, Inc. | Method for delivery of therapeutic agents to the heart |
| WO1996026742A1 (en) * | 1995-02-28 | 1996-09-06 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
| US5800539A (en) * | 1995-11-08 | 1998-09-01 | Emory University | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease |
| AU745409B2 (en) * | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
| US6045565A (en) * | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
| CA2296704C (en) * | 1997-07-14 | 2010-10-19 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
| US7078387B1 (en) * | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| WO2000057922A1 (en) * | 1999-03-30 | 2000-10-05 | Ran Kornowski | Intramyocardial injection of autologous bone marrow |
| US7097832B1 (en) * | 1999-03-30 | 2006-08-29 | Myocardial Therapeutics, Inc. | Intramyocardial injection of autologous bone marrow |
| AU2001284695A1 (en) * | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
-
2002
- 2002-01-23 EP EP02720895A patent/EP1361896A2/en not_active Withdrawn
- 2002-01-23 US US10/057,409 patent/US20020172663A1/en not_active Abandoned
- 2002-01-23 WO PCT/US2002/003118 patent/WO2002064157A2/en not_active Ceased
- 2002-01-23 CA CA002433936A patent/CA2433936A1/en not_active Abandoned
- 2002-01-23 JP JP2002563950A patent/JP2005501802A/ja active Pending
-
2008
- 2008-05-16 US US12/122,561 patent/US20080254109A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011503207A (ja) * | 2007-11-16 | 2011-01-27 | サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
| JP2015007063A (ja) * | 2007-11-16 | 2015-01-15 | サン ディエゴ ステート ユニバーシティ リサーチ ファウンデーション | 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1361896A2 (en) | 2003-11-19 |
| WO2002064157A3 (en) | 2003-08-07 |
| CA2433936A1 (en) | 2002-08-22 |
| US20020172663A1 (en) | 2002-11-21 |
| WO2002064157A2 (en) | 2002-08-22 |
| WO2002064157A9 (en) | 2003-06-05 |
| US20080254109A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005501802A (ja) | 虚血心筋を処置するための限局性心筋注入方法 | |
| CN1136920C (zh) | 基因转移介导的血管形成疗法 | |
| US20090082293A1 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
| JP2011225611A (ja) | 遺伝子転移媒介の血管形成療法 | |
| JP3865632B2 (ja) | 心筋症遺伝子治療 | |
| AU784392B2 (en) | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery | |
| AU772857B2 (en) | Method of inducing angiogenesis | |
| CN100350979C (zh) | 核酸和血管活性剂相组合用于加强的基因投递 | |
| JP2002515065A (ja) | 脈管形成トランスジーンのインビボ送達により心不全および心室再構成を処置するための技術および組成物 | |
| Kastrup, Erik Jørgensen, Viktor Drvota | Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium. Therapeutic angiogenesis | |
| AU2006200170B2 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| US20160296674A1 (en) | Nucleic acid based cardiovascular therapeutics | |
| HK1008979B (en) | Gene transfer-mediated angiogenesis therapy | |
| HK1094944A (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050124 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060713 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080618 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080908 |